<?php
/**
 * Forum topic creation script for HER-096
 * Generated: 2026-11-05 by MinMaxMuscle daily discovery agent
 * Run via WP-CLI or directly on the WordPress host:
 *   php 20261105_her-096.php
 * Requires: WordPress environment loaded, Asgaros Forum active
 */

// Load WordPress if not already loaded
if ( ! defined( 'ABSPATH' ) ) {
    // Adjust path as needed for your server
    require_once '/var/www/html/wp-load.php';
}

$topic_title   = 'New Research Thread: HER-096 — CDNF-Mimetic Peptidomimetic for Parkinson\'s Disease Phase 2';
$topic_content = '<p><strong>HER-096</strong> is a ~1,000 Da retro-inverso-isomerized peptidomimetic developed by Herantis Pharma (Helsinki, Finland) as a potential disease-modifying therapy for Parkinson\'s disease.</p>

<p><strong>Key facts:</strong></p>
<ul>
<li>Derived from the C-terminal domain of CDNF (cerebral dopamine neurotrophic factor)</li>
<li>Crosses the blood-brain barrier after subcutaneous injection — unlike native CDNF, which requires direct brain infusion</li>
<li>Mechanism: suppresses ER stress (IRE1α/ATF6) and neuroinflammation in dopaminergic neurons</li>
<li>Phase 1b (Parkinson\'s patients, 300 mg twice-weekly SC) completed October 2025 — positive topline data with early biological signals</li>
<li>Phase 2 (~100 early-stage PD patients, 9-month double-blind + 6-month open-label) — CTA submission Q4 2026, first dosing H1 2027</li>
<li>Funded with €8 million EU Horizon grant</li>
<li>November 5, 2026: peer-reviewed clinical evidence published validating the Phase 2 study design</li>
</ul>

<p><strong>Why this matters:</strong> No approved Parkinson\'s drug has demonstrated disease modification in a Phase 3 trial. All current therapies are symptomatic. HER-096 targets upstream neuronal death pathways (ER stress/UPR), not dopamine replacement. If Phase 2 succeeds, this would be the first class of BBB-penetrant peptidomimetics in Phase 3 for Parkinson\'s — a potential breakthrough in a very difficult indication.</p>

<p>This is early-stage (Phase 1b) but the mechanism is well-grounded in CDNF neurobiology and the retro-inverso design is elegant. Worth following.</p>

<p>See the full research dossier at <a href="https://minmaxmuscle.com/peptides/her-096">minmaxmuscle.com/peptides/her-096</a></p>

<p><em>Research compounds discussed for educational purposes. Not FDA-approved for human use. Consult a healthcare provider before use.</em></p>';

$forum_id = 1; // Adjust to actual forum ID
$author_id = 1; // Adjust to actual admin user ID

// Check if Asgaros Forum is available
if ( function_exists( 'af_add_topic' ) ) {
    $result = af_add_topic( $forum_id, $author_id, $topic_title, $topic_content );
    echo "Topic created: " . ( $result ? "Success (ID: $result)" : "Failed" ) . "\n";
} else {
    // Fallback: create as a regular WP post
    $post_id = wp_insert_post( [
        'post_title'   => $topic_title,
        'post_content' => $topic_content,
        'post_status'  => 'publish',
        'post_author'  => $author_id,
        'post_type'    => 'post',
    ] );
    echo "Fallback post created: " . ( is_wp_error( $post_id ) ? $post_id->get_error_message() : "Success (ID: $post_id)" ) . "\n";
}
